Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
STAB1 inhibitor
DRUG CLASS:
STAB1 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
bexmarilimab (6)
bexmarilimab (6)
›
Associations
(6)
News
Trials
VERI cancer hierarchy
Reset Filters
IFNG-L
Cholangiocarcinoma
IFNG-L
Cholangiocarcinoma
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
TNFA-L
Cholangiocarcinoma
TNFA-L
Cholangiocarcinoma
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
IFNG-L
Melanoma
IFNG-L
Melanoma
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
TNFA-L
Melanoma
TNFA-L
Melanoma
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
IFNG-L
Gastric Cancer
IFNG-L
Gastric Cancer
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
TNFA-L
Gastric Cancer
TNFA-L
Gastric Cancer
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
bexmarilimab
Sensitive: C3 – Early Trials
bexmarilimab
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.